Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Alejo Rodriguez-VidaPablo MarotoAlbert FontCristina MartinBegoña MelladoAlex CorberaMayra OrrilloOscar ReigRosa QuerolAlejandro Rios-HoyoLaia CanoJudith AlonsoGemma MartinezSusana GaltesAlvaro TausMaria Martinez-GarciaNuria JuanpereOscar JuanJoaquim BellmuntPublished in: British journal of cancer (2022)
Avelumab plus carboplatin has an acceptable safety profile and was associated with a prolonged OS given the heavily pretreated population.